Anixa Biosciences (NASDAQ:ANIX) CEO Acquires $11,190.00 in Stock

Anixa Biosciences Inc (NASDAQ:ANIX) CEO Amit Kumar bought 3,000 shares of Anixa Biosciences stock in a transaction dated Friday, July 24th. The shares were acquired at an average cost of $3.73 per share, with a total value of $11,190.00. Following the completion of the purchase, the chief executive officer owned 643,812 shares in the company, valued at approximately $2,401,418.76. This trade represents a 0.47% increase in their ownership of the stock. The acquisition was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this link.

Amit Kumar also recently made the following trade(s):

• On Monday, July 20th, Amit Kumar bought 5,000 shares of Anixa Biosciences stock. The shares were acquired at an average price of $3.46 per share, for a total transaction of $17,300.00.
• On Monday, July 27th, Amit Kumar purchased 3,188 shares of Anixa Biosciences stock. The stock was bought at an average cost of $3.37 per share, for a total transaction of $10,743.56.
• On Monday, July 27th, Amit Kumar purchased 5,000 shares of Anixa Biosciences stock. The stock was bought at an average cost of $3.44 per share, with a total value of $17,200.00.
• On Friday, July 10th, Amit Kumar acquired 5,000 shares of Anixa Biosciences stock. The shares were bought at an average price of $3.04 per share, with a total value of $15,200.00.
• On Friday, June 12th, Amit Kumar acquired 21,000 shares of Anixa Biosciences stock. The shares were bought at an average price of $2.50 per share, with a total value of $52,500.00.

Anixa Biosciences Stock Up 2.3%

ANIX opened at $3.56 on Friday. The firm’s fifty day simple moving average is $2.96 and its two-hundred day simple moving average is $2.92. Anixa Biosciences Inc has a 52-week low of $2.32 and a 52-week high of $5.46. The company has a market cap of $121.12 million, a price-to-earnings ratio of -11.48 and a beta of 0.59.

Anixa Biosciences (NASDAQ:ANIX) last released its earnings results on Wednesday, June 10th. The company reported ($0.07) EPS for the quarter, topping analysts’ consensus estimates of ($0.10) by $0.03. On average, research analysts forecast that Anixa Biosciences Inc will post -0.31 EPS for the current year.

Institutional Trading of Anixa Biosciences

A number of hedge funds and other institutional investors have recently modified their holdings of the stock. Bank of America Corp DE grew its holdings in shares of Anixa Biosciences by 1.7% in the third quarter. Bank of America Corp DE now owns 213,955 shares of the company’s stock valued at $706,000 after purchasing an additional 3,645 shares during the period. Prosperity Wealth Management Inc. raised its stake in Anixa Biosciences by 14.5% during the third quarter. Prosperity Wealth Management Inc. now owns 41,800 shares of the company’s stock worth $138,000 after purchasing an additional 5,300 shares during the period. Geode Capital Management LLC boosted its holdings in Anixa Biosciences by 2.1% in the 4th quarter. Geode Capital Management LLC now owns 350,915 shares of the company’s stock valued at $1,095,000 after purchasing an additional 7,271 shares during the last quarter. Renaissance Technologies LLC boosted its holdings in Anixa Biosciences by 13.6% in the 1st quarter. Renaissance Technologies LLC now owns 61,173 shares of the company’s stock valued at $158,000 after purchasing an additional 7,300 shares during the last quarter. Finally, Westside Investment Management Inc. grew its stake in shares of Anixa Biosciences by 25.7% in the 4th quarter. Westside Investment Management Inc. now owns 44,000 shares of the company’s stock valued at $137,000 after buying an additional 9,000 shares during the period. 29.13% of the stock is owned by institutional investors and hedge funds.

Analyst Ratings Changes

A number of equities analysts have commented on ANIX shares. Wall Street Zen raised Anixa Biosciences from a “sell” rating to a “hold” rating in a report on Saturday, June 20th. D. Boral Capital reaffirmed a “buy” rating and issued a $10.00 price target on shares of Anixa Biosciences in a research note on Tuesday, June 30th. Weiss Ratings reiterated a “sell (e+)” rating on shares of Anixa Biosciences in a research report on Wednesday, June 17th. Zacks Research raised Anixa Biosciences from a “hold” rating to a “strong-buy” rating in a research note on Tuesday, July 21st. Finally, HC Wainwright restated a “buy” rating on shares of Anixa Biosciences in a report on Friday, June 12th. One research analyst has rated the stock with a Strong Buy rating, three have given a Buy rating and one has issued a Sell rating to the stock. According to MarketBeat, the company has a consensus rating of “Moderate Buy” and a consensus target price of $8.50.

Anixa Biosciences Company Profile

Anixa Biosciences is a clinical-stage immuno-oncology and infectious disease company developing novel cell-based immunotherapies and vaccine platforms. Through its Anixa Therapeutics division, the company is advancing antibody and T-cell modalities, including an ovarian cancer immunotherapy candidate and a COVID-19 vaccine leveraging a proprietary virus-like particle (VLP) technology. Its research pipeline emphasizes modular vaccine design and personalized cancer cell therapy aimed at inducing durable immune responses against solid tumors.

In parallel, Anixa Diagnostics is developing the ADAPT diagnostic platform, a high-throughput proteomics approach using engineered peptides derived from spider venom.